BS_063ERW0R
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 9.236
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.959 |
| 2 | BS_CQSAJ7BF | DNET | — | 0.958 |
| 3 | BS_K5802F84 | pilocytic astrocytoma | — | 0.950 |
| 4 | BS_92VDQ0NE | Ganglioglioma | — | 0.944 |
| 5 | BS_0T17SY47 | low-grade glioma | — | 0.943 |
| 6 | SRR1339740 | GTEX | — | 0.940 |
| 7 | MNG14 | — | — | 0.938 |
| 8 | MNG540 | — | — | 0.937 |
| 9 | BS_YNEQJ6AH | DNET | — | 0.935 |
| 10 | TCGA-G2-A2EK-01A-22R-A18C-07 | — | — | 0.934 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.383 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.172 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.133 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.102 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.021 | Remibrutinib | — uncovered |